ORION CORPORATION
PRESS RELEASE
6 October 2022 at 9.30 EEST
Orion publishes Interim Report for January-September 2022 on Thursday 20October 2022
Orion will publish Interim Report for January-September 2022 on Thursday, 20 October 2022 at approximately 12.00 noon EEST. The report and related presentation material will be available on the company's website at www.orion.fi/en/investorsafter publishing.
Webcast and conference call
A webcast and a conference call for analysts, investors and media will be held on Thursday, 20 October 2022 at 13.30 EEST. The event will be held only online and by conference call.
A link to the live webcast will be available on Orion's website at www.orion.fi/en/investors. A recording of the event will be available on the website later the same day.
To participate the conference call, please dial:
Finland: +358 9 2319 5436
Sweden: +46 8 5051 0086
UK: +44 33 0551 0211
USA: +1 646 843 4609
PIN: 8122705#
Silent period
The silent period preceding the publication is ongoing and continues until the disclosure.
Contact person:
Tuukka Hirvonen, Investor Relations, Orion Corporation
tel. +358 10 426 2721
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are oncology and pain. Orion's net sales in 2021 amounted to EUR 1,041 million and the company had about 3,350 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
